Clinical trial · Interventional
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
Wedge Resection for Ground-glass Opacity-featured Lung Cancer With Size Less Than 2cm and Consolidation-to-tumor Ratio Between 0.25 to 0.5: a Single-arm, Multi-center, Prospective, Confirmatory Phase III Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a clinical trial from the Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1020. The goal of this clinical trial is to confirm the therapeutic effect of Wedge resection for ground-glass opacity-featured lung cancer with a size less than 2cm and a consolidation-to-tumor ratio between 0.25 to 0.5.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ground-glass Opacity | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Wedge Resection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Wedge resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Wedge resection
- description
- Wedge resection is performed for early-stage lung cancer to remove a wedge-shaped section of lung tissue.
- interventionNames
- Procedure: Wedge resection
Primary outcomes (1)
- measure
- 5-year overall survival
- timeFrame
- 5 years
- description
- The event is defined as the death due to any causes.
Secondary outcomes (6)
- measure
- 5-year recurrence-free survival
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who sign the informed consent form and are willing to complete the study according to the plan; 2. Aged from 18 to 80 years old; 3. ECOG equals 0 or 1; 4. Not receiving lung cancer surgery before; 5. Intraoperative or postoperative pathologic diagnosis of lung adenocarcinoma; 6. Single lung nodules with ground-glass dominant or pure ground-glass on CT, or multiple lung nodules with the major lesion being the aforementioned nodules; 7. The nodule has a consolidation-to-tumor ratio (CTR) between 0.25 and 0.5 (including 0.25 and 0.5), and the nodule size is less than or equal to 2 cm; 8. peripheral type of nodes, namely, nodes in the outer 1/3 of the lung field. 9. cT1N0M0 tumors; 10. Complete tumor resection by wedge resection as assessed by the surgeon; 11. Not receiving chemotherapy or radiotherapy before. Exclusion Criteria: 1. Postoperative pathologic diagnosis of adenocarcinoma in situ or minimally invasive adenocarcinoma. 2. CTR is not between 0.25-0.5 or nodule size greater than 2 cm; 3. Cannot be completely resected by wedge resection; 4. Invasive lung adenocarcinoma or lung malignancy other than lung adenocarcinoma diagnosed cytologically or pathologically; 5. Receiving lung cancer surgery before; 6. Receiving radiotherapy or chemotherapy.
References
Publications (1)
- DERIVEDLi T, Fu F, Zhang Y, Chen H. Protocol for a single-arm, multicenter, prospective, confirmatory phase III trial of wedge resection for invasive ground glass opacity-featured lung cancer with a size </=2 cm and a consolidation tumor ratio between 0.25 and 0.5 (ECTOP-1020 study). J Thorac Dis. 2024 Jul 30;16(7):4711-4718. doi: 10.21037/jtd-24-440. Epub 2024 Jul 9. PMID 39144343